Serán More Than Doubles Clinical Manufacturing Capacity
CDMO Serán BioScience recently announced that it has completed an expansion to increase the number of process manufacturing suites at its facility in Bend, Oregon, from 6 to 14, adding approximately 130% more cGMP clinical manufacturing capacity.
Adding eight state-of-the-art suites will boost the flexible capacity for late-stage clinical trial supplies of small-molecule medicines. Serán’s ‘Right-From-the-Start’ approach includes enhancing bioavailability by improving permeability and solubility, matrix tablet- and multiparticulate-based modified release, extensive capsule and tablet capabilities, and engineered particles for inhalation.
“Serán continues to see high demand for science-based drug product services,” commented Dan Smithey, President, CEO and Co-founder of Serán BioScience. “We are excited to announce the expansion at the site, where we can now provide mid- and large-scale manufacturing unit operations to support our clients’ journey from first-in-human studies through to pivotal trials and registration.”
The new suites within Serán’s 90,000-sq ft campus in Bend feature the latest technologies for transformative pharmaceutical dosage-form solutions. The site offers clinical manufacturing for a wide range of oral solid and inhaled dosage forms, including nano milling, micronization, particle engineering, spray-dried dispersions, twin-screw melt extrusion, tablet compression, coating, encapsulation, and clinical packaging and labeling.
